Finkelstein Thompson LLP Announces Investigation of Cornerstone Therapeutics
WASHINGTON -- September 16, 2013
The law firm of Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of Cornerstone Therapeutics Inc. (NASDAQ: CRTX)
(“Cornerstone” or “the Company”), concerning the Company’s proposed
acquisition by Chiesi Farmaceutici S. P. A. (“Chiesi”). Under the terms of the
merger agreement, Cornerstone shareholders will receive $9.50 in cash for each
share of Cornerstone common stock they own. Chiesi currently owns 58% of
Cornerstone’s outstanding common shares. The total transaction is valued at
approximately $107 million. At least one analyst has set a target price of
$14.00 for Cornerstone shares.
The investigation is focused on the potential unfairness of the consideration
to shareholders, the process by which Cornerstone’s Board of Directors
considered the transaction, and potential conflicts of interest among the
Company’s Board members.
If you are interested in discussing your rights as a Cornerstone shareholder,
or have information relating to this investigation, please contact Finkelstein
Thompson’s Washington, DC offices at (202)-337-8000 or by email at
Finkelstein Thompson LLP has spent over three decades delivering outstanding
representation to institutional and individual clients in financial
litigation, and has been appointed as lead or co-counsel in dozens of
shareholder class actions. Indeed, the firm has served in leadership roles in
cases that have recovered over $1 billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our website at
www.finkelsteinthompson.com. Attorney advising. Prior results do not guarantee
Finkelstein Thompson LLP
Rosalee B.C. Thomas, 877-337-1050
Press spacebar to pause and continue. Press esc to stop.